SCHOTT Pharma AG & Co. KGaA
25.55
EUR
-0.25
(-0.97%)
ISIN
DE000A3ENQ51
Return %
Stock
S&P 500
1Y
27.11
14.20
3Y
-14.95
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Christian Mias
- Full Time Employees
- 4,811
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Hattenbergstrasse 10 Mainz RP Germany 55122
- IPO Date
- Sep 28, 2023
- Website
- schott.com
- Similar Companies
- Business
- SCHOTT Pharma AG & Co. KGaA develops and manufactures drug containment and delivery systems for injectable drugs, including prefillable glass and polymer syringes such as syriQ BioPure glass syringes for biologics and SCHOTT TOPPAC cyclic olefin copolymer syringes; cartridges for pen injectors and dual-chamber systems; vials for secure storage of liquid formulations; and ampoules for stable containment from production to administration; alongside analytical lab services encompassing chemical durability testing and glass delamination screening, development support, fill-and-finish capabilities, and regulatory services for pharmaceutical companies, biotechs, and contract development and manufacturing organizations. The company operates 16 GMP-compliant manufacturing sites across Europe, North America, South America, and Asia, including facilities in Germany, the United States, Mexico, Brazil, Colombia, Argentina, China, Indonesia, India, Hungary, Switzerland, France, and others, serving over 1,800 customers including the top 30 global pharma manufacturers for injectables. Headquartered in Mainz, Germany, and founded over 130 years ago as part of the SCHOTT heritage from Otto Schott's glass innovations, it remains majority owned by SCHOTT AG under the Carl Zeiss Foundation and trades on the Frankfurt Stock Exchange under ticker 1SXP.F with approximately 4,700 employees generating EUR 957 million in revenue for fiscal year 2024. In May 2025, SCHOTT Pharma welcomed TPG as a new strategic partner in its SCHOTT Poonawalla joint venture in India with Serum Institute of India, where TPG acquired a 35% stake to fuel expansion in vaccine packaging and delivery amid India's rise as a pharma hub, while SCHOTT retains 50% ownership; the deal, expected to close in the first half of 2025, leverages TPG's healthcare expertise for supply chain resilience and innovation. The company also received a EUR 2.78 million subsidy from the Serbian government in 2025 to establish a new ampoule production facility in Jagodina, Serbia, targeting 176 new jobs by year-end and up to 350 in expansion, with EUR 19 million in investments by 2027 for injectables like painkillers and anesthetics. Additionally, SCHOTT Pharma launched ready-to-use polymer cartridges to meet rising demand for biologics and patient-friendly administration, reported strong fiscal 2025 Q2 EBITDA growth of 63% year-over-year to EUR 72 million driven by product mix shifts, and continues capacity expansions supporting mRNA and GLP-1 therapies.